Merck
HomeWebinarsThe Dynamics of SARS-CoV-2 Specific Antibody Responses in COVID-19 Patients

The Dynamics of SARS-CoV-2 Specific Antibody Responses in COVID-19 Patients



WEBINAR

In response to the high demands of the research community, our R&D Scientists developed three new MILLIPLEX® multiplex kits, each for the qualitative detection of IgG, IgM, or IgA antibodies which recognize the SARS-CoV-2 antigens, S1, S2, RBD, and N, in human serum/plasma samples. These assays are for research use only (RUO) and not intended for use in clinical or for diagnostic purposes.

In this webinar, results are presented from using these kits to analyze samples from patients determined positive or negative by PCR for COVID-19.

  • Each MILLIPLEX® SARS-CoV-2 kit detects one immunoglobulin type: IgG, IgM, IgA
  • Each MILLIPLEX® SARS-CoV-2 kit is selectable for the antigen(s) you wish to detect: S1, S2, RBD, N

MILLIPLEX® SARS-CoV-2 assay key points: 96-well assay format; 2-hour primary incubation; 25 µL per well of 1:100 – 1:200 diluted sample; qualitative assay; kits contain positive and negative assay performance verification beads; all readouts are in mean fluorescence intensity (MFI); customers should include COVID negative samples to determine experiment MFI cutoff

For Research Use Only. Not For Use In Diagnostic Procedures.

Speakers

Christine S. Falk, Ph.D.

Christine S. Falk, Ph.D.

Hannover Medical School

Full Professor for Transplant Immunology; Director, Institute of Transplant Immunology

Christine S. Falk, PhD., is a full professor for Transplant Immunology and director of the Institute of Transplant Immunology at Hannover Medical School (MHH). She focuses on mechanisms of ischemia/reperfusion injury and consequences for innate and adaptive immunity, especially tissue-resident T and NK cells in the context of lung, heart, and kidney transplantation. She graduated with a Ph.D. at the Institute of Immunology at Ludwig-Maximilians University in Munich, Germany, in the field of tumor immunology. She continued to work on T and NK cell recognition of solid tumors as a postdoc fellow at the Institute of Molecular Immunology, Helmholtz Centre Munich. In 2004, she received her Venia Legendi at LMU for Human Immunology. From 2006 to 2010, she worked at the German Cancer Research Centre (DKFZ) in Heidelberg, Germany, as group leader of the Research Group “Immune Monitoring” with a strong interest in the improvement of cancer immunotherapy by understanding the mechanisms involved in treatment resistance.

Christine Falk has a long-term research interest in transplant and tumor immunology and the interface to infectious diseases in solid organ transplantation. Major aspects of her research are tissue-resident lymphocytes and the identification of "common denominators" of tumor vs. organ rejection and protection from infection. She published more than 150 peer articles in international peer-reviewed journals and received the Walter Schulz award for Tumor Immunology. At MHH, she is a trusted lecturer of the DFG, a member of dissertation and research committees, and vice president of the German Society of Immunology (DGfI). Since 2014, she serves as a board member of the German Cancer Aid Foundation and an editorial board member of several scientific journals.

Christine Kornmeier

Christine Kornmeier

Merck

Global Product Manager, Immunoassay Platform Solutions

Christine Kornmeier joined the MILLIPLEX® Product Management team in 2016 after a career in discovery research biology focusing on Inflammatory Mediators at Pfizer and legacy Pharmacia and G.D. Searle/Monsanto. She is currently a Product Manager for the MILLIPLEX® immunoassays.

Webinar Information

Protein biology

  • Protein quantitation
  • Duration:32m

  • Language:English

  • Presented:Fri, December 11, 2020